Orforglipron (Foundayo)

A once-daily GLP-1 pill from Eli Lilly, sold as Foundayo for weight management. It's a small molecule, not a peptide, so you can take it with or without food.

Evidence: Extensive clinical research
Half-life: ~39 hours
Sources: 5 cited

Is orforglipron FDA-approved?

FDA-approved as Foundayo on April 1, 2026 for chronic weight management in adults. Taken once a day, with or without food: the label sets no wait before eating.

Overview

Orforglipron switches on the same GLP-1 receptor as the injectable medicines but is a small chemical that survives digestion. The FDA approved it as Foundayo in April 2026 for adults with obesity, or with overweight and at least one weight-related health problem, alongside diet and exercise. In the 72-week ATTAIN-1 trial in adults with obesity, the highest dose led to about 11% average weight loss, versus about 2% on placebo. The ACHIEVE trials test it in type 2 diabetes.

How it works

It binds the GLP-1 receptor and triggers the same effects as GLP-1 shots: more insulin when sugar is high, slower stomach emptying and less appetite.

How long does orforglipron stay in the body?

About 29 to 49 hours, so it builds to a steady level after about a week of daily pills. Levels peak 4 to 8 hours after a dose. About 77% of a dose is absorbed, and food lowers that only a little.

What it's studied for

Obesity
Type 2 diabetes
Keeping weight off after stopping injectables

Reported side effects

Nausea, constipation, diarrhea, vomiting, indigestion
Slows the stomach, which can change how other pills are absorbed
Boxed warning: thyroid C-cell tumors are a GLP-1 class warning. Orforglipron didn't cause them in rodents, but the label still rules it out for people with a personal or family history of medullary thyroid cancer or MEN 2.

How should orforglipron be stored?

Room temperature, in the original bottle.

Sources

The studies and prescribing labels this page is written from.